The evolving role of lenalidomide in non-Hodgkin lymphoma

Leukemia & Lymphoma
Natalie GalaninaChadi Nabhan

Abstract

Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, lenalidomide has emerged as one such option. Lenalidomide demonstrates clinically significant activity with a favorable safety profile as a single agent, as well as in combination therapy. Herein, we review accumulated clinical data on lenalidomide, with particular reference to patients with first-line and relapsed/refractory mantle cell lymphoma, indolent lymphoma, and diffuse large B-cell lymphoma.

References

Apr 12, 2001·The Journal of Biological Chemistry·J A KeiferA S Baldwin
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francisco J Hernandez-IlizaliturriMyron S Czuczman
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter H WiernikThomas M Habermann
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigJulie M Vose
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Apr 21, 2011·Leukemia & Lymphoma·Pier Luigi ZinzaniMichele Baccarani
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyThomas E Witzig
Sep 14, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniT E Witzig
Oct 12, 2013·Blood·Hervé Falet
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Jul 22, 2014·Nature·Eric S FischerNicolas H Thomä
Aug 12, 2014·Nature Structural & Molecular Biology·Philip P ChamberlainBrian E Cathers
Aug 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grzegorz S NowakowskiThomas E Witzig
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Víctor M Castellano-MegíasFrancisco Colina-Ruizdelgado
Jan 30, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elise A ChongStephen J Schuster
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John G GribbenFranck Morschhauser

❮ Previous
Next ❯

Citations

Jul 7, 2017·Leukemia & Lymphoma·Bruna Maria Bereta SouzaHelio Moraes-Souza
May 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah A HolsteinPhilip L McCarthy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.